Last Update

2016-08-28T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Brian Issell?

Dr. Brian F. Issell

HQ Phone: (808) 586-3010

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

University of Hawaii Cancer Center

701 Ilalo Street

Honolulu, Hawaii 96813

United States

Company Description

The University of Hawai'i Cancer Center is the only National Cancer Institute-designated center in Hawai'i and the Pacific. The Center's mission is to reduce the burden of cancer through research, education, and patient care with an emphasis on the unique ... more

Find other employees at this company (190)

Background Information

Employment History

Head of the Clinical and Translational Research Program

University of Hawaii

Vice President of Clinical Research and Medical Director of Academic Affairs

Scripps Memorial Hospital

Education

MD

Web References (194 Total References)


Brian F. Issell, MD

www.uhcancercenter.org [cached]

Brian F. Issell, MD

...
Brian F. Issell, MD \n This e-mail address is being protected from spambots. You need JavaScript enabled to view it. " _mce_href="mailto: This e-mail address is being protected from spambots. You need JavaScript enabled to view it. "> This e-mail address is being protected from spambots. You need JavaScript enabled to view it. | (808) 356-5794 Brian F. Issell, MD Clinical Professor
...
Dr. Issell's career has been committed to clinical and translational research to improve the care of cancer patients. He has been a clinical and translational investigator, educator, administrator and practicing medical oncologist for over 30 years. From 1978-1983, he led the preclinical to clinical transition of several notable anticancer drugs in the US including cisplatin, carboplatin and etoposide, while working at Bristol Myers (now Bristol Myers Squibb). From 1983-1988, he led the initial generation of monoclonal antibody products and the preclinical and clinical development of both monoclonal antibody products and cytokines (including IL-2) while working at Cetus Corporation (now Novatis). From 1988-1999, he was Director of the University of Hawaii Cancer Center. In this role he led the development of new programs in natural products drug discovery, prevention and control and clinical science and the acquisition of first an NCI P20 Cancer Center Planning Grant and then a P30 Cancer Center Support (Core) Grant. From 1999 to 2006, he was Director of the Center's Clinical Sciences/Clinical Trials. He has been PI on multiple clinical research projects (including Phase I studies) funded by R01, R21, U01 and U10 mechanisms. He was Program Director of a K12 award for training clinical investigators and participated in T32 and R25 training awards held by the Cancer Center. From December 2006-December 2010, he was Vice President of Clinical Research/Medical Director of Academic Affairs for Scripps Health and Director of Clinical Research, Scripps Translational Science Institute which was awarded an NIH CTSA under his leadership of the clinical and regulatory components. He led the expansion of clinical research throughout Scripps Health multi-hospital system and took it to a new level of excellence through intra- and inter-institutional collaborations and the training and support of outstanding clinical investigators. In 2011 he returned to the University of Hawaii Cancer Center as Associate Director of Clinical Sciences and Translational Research to help lead its transformation to a new level of clinical investigation.
Selected Publications Lillie, E.; Patay, B.; Diamant, J.; Issell, B.; Topol, E. The n-of -1 clinical trial: the ultimate strategy for individualizing medicine? Personalized Medicine 8: (2) 161-173, 2011. Maskarinec, G.; Pagano, I.; Lurie, G; Bantum, E.; Gotay,C.C.; Issell, B.F.; Factors Affecting Survival among Women with Breast Cancer in Hawaii. Journal of Women's Health, 20: (2) 231-237, 2011.
...
Issell, B.F.; Gotay, C.C.; Pagano, I; Franke, A.A.; Using Quality of Life Measures in a Phase I Clinical Trial of Noni in Patients with Advanced Cancer to Select a Phase II Dose. Journal of Dietary Supplements, 6: (4) 347-359, 2009. Issell, B.F.; Franke, A.; Fielding, R.M.: Pharmacokinetic Study of Noni Fruit Extract. Journal of Dietary Supplements, 5: (4) 373-382, 2008.


Faculty

www.uhcancercenter.org [cached]

Brian F. Issell, MD


Faculty

www.uhcancercenter.org [cached]

Brian F. Issell, MD

Researcher (Professor) and Clinical Member


Faculty

www.uhcancercenter.org [cached]

Brian F. Issell, MD

Researcher (Professor) and Clinical Member


Brian F. Issell, MD

www.uhcancercenter.org [cached]

Brian F. Issell, MD

...
Brian F. Issell, MD \n This e-mail address is being protected from spambots. You need JavaScript enabled to view it. " _mce_href="mailto: This e-mail address is being protected from spambots. You need JavaScript enabled to view it. "> This e-mail address is being protected from spambots. You need JavaScript enabled to view it. | (808) 356-5794 Brian F. Issell, MD Researcher (Professor) and Clinical Member
...
Dr. Issell's career has been committed to clinical and translational research to improve the care of cancer patients. He has been a clinical and translational investigator, educator, administrator and practicing medical oncologist for over 30 years. From 1978-1983, he led the preclinical to clinical transition of several notable anticancer drugs in the US including cisplatin, carboplatin and etoposide, while working at Bristol Myers (now Bristol Myers Squibb). From 1983-1988, he led the initial generation of monoclonal antibody products and the preclinical and clinical development of both monoclonal antibody products and cytokines (including IL-2) while working at Cetus Corporation (now Novatis). From 1988-1999, he was Director of the University of Hawaii Cancer Center. In this role he led the development of new programs in natural products drug discovery, prevention and control and clinical science and the acquisition of first an NCI P20 Cancer Center Planning Grant and then a P30 Cancer Center Support (Core) Grant. From 1999 to 2006, he was Director of the Center's Clinical Sciences/Clinical Trials. He has been PI on multiple clinical research projects (including Phase I studies) funded by R01, R21, U01 and U10 mechanisms. He was Program Director of a K12 award for training clinical investigators and participated in T32 and R25 training awards held by the Cancer Center. From December 2006-December 2010, he was Vice President of Clinical Research/Medical Director of Academic Affairs for Scripps Health and Director of Clinical Research, Scripps Translational Science Institute which was awarded an NIH CTSA under his leadership of the clinical and regulatory components. He led the expansion of clinical research throughout Scripps Health multi-hospital system and took it to a new level of excellence through intra- and inter-institutional collaborations and the training and support of outstanding clinical investigators. In 2011 he returned to the University of Hawaii Cancer Center as Associate Director of Clinical Sciences and Translational Research to help lead its transformation to a new level of clinical investigation.
Publications Lillie, E.; Patay, B.; Diamant, J.; Issell, B.; Topol, E. The n-of -1 clinical trial: the ultimate strategy for individualizing medicine? Personalized Medicine 8: (2) 161-173, 2011. Maskarinec, G.; Pagano, I.; Lurie, G; Bantum, E.; Gotay,C.C.; Issell, B.F.; Factors Affecting Survival among Women with Breast Cancer in Hawaii. Journal of Women's Health, 20: (2) 231-237, 2011.
...
Issell, B.F.; Gotay, C.C.; Pagano, I; Franke, A.A.; Using Quality of Life Measures in a Phase I Clinical Trial of Noni in Patients with Advanced Cancer to Select a Phase II Dose. Journal of Dietary Supplements, 6: (4) 347-359, 2009. Issell, B.F.; Franke, A.; Fielding, R.M.: Pharmacokinetic Study of Noni Fruit Extract. Journal of Dietary Supplements, 5: (4) 373-382, 2008.

Similar Profiles

Other People with this Name

Other people with the name Issell

Natasha Issell
ARC Plastic Surgery

Amanda Issell
The Lockyer Doctors

George Issell
The Windsor Transportation Club Inc

Hagen Issell
NZTC Pasifika

Sheila Issell
Auslan Connections

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory